Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANG003 in Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
NCT06052293Phase 1Completed
- Sponsor
- Anagram Therapeutics
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ANG003 in exocrine pancreatic insufficiency (EPI) (4 arms), sponsored by Anagram Therapeutics. Primary endpoint: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and AEs Leading to Study Discontinuation at 9 days. Started Aug 2023; status: completed.
02
Drugs
ANG003
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT06052293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052293.